Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.32 |
| ▸ | GRM8 | O00222 | 3/20 | 0.32 |
| ▸ | GRM6 | O15303 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394133 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL5390585 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL5394130 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL5405686 | 1.00 | FUCA1 (0.32) | FUCA1GRM4GRM8GRM6ALDH1A1 | |
| SCHEMBL6880715 | 0.87 | CYP1A2 (0.34) | — | |
| SCHEMBL5382379 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5394072 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5394201 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5388548 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL5382375 | 0.78 | CYP1A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1495160-A | I-substituted-1-aminomethyl-cycloalkane derivative (gabapentin analogs), its preparation and application for curing neuropathy | ��ʲ | 2004-05-12 | — | — | CN | claimed |
| CN-1279674-A | 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders | WARNER LAMBERT CO (US) | 2001-01-10 | — | — | CN | claimed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| CN-1878546-A | Combination comprising an alpha-2 delta ligand and an SSRI and/or SNRI for the treatment of depression and anxiety | WARNER LAMBERT CO (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1726015-A | Alpha 2 delta ligands for different pharmaceutical uses | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1635887-A | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | WARNER LAMBERT CO (US) | 2005-07-06 | — | — | CN | disclosed |
| CN-1625393-A | Alpha 2 delta ligands to treat tinnitus | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1495160-A | I-substituted-1-aminomethyl-cycloalkane derivative (gabapentin analogs), its preparation and application for curing neuropathy | ��ʲ | 2004-05-12 | — | — | CN | disclosed |
| CN-1131855-C | 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders | WARNER-LAMBERT CO. (US) | 2003-12-24 | — | — | CN | disclosed |
| CN-1279674-A | 1-substituted-1-aminomethyl-cycloalkane derivatives (= gabapentin analogues), their preparation and their use in the treatment of neurological disorders | WARNER LAMBERT CO (US) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | FUCA1 1432/4885GRM4 979/4885GRM8 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.